A practical reference on NR1D1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-07 and is reviewed periodically as new material appears.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
=== Brand names === Finasteride is marketed primarily under the brand names Propecia, for pattern hair loss, and Proscar, for BPH, both of which are products of Merck & Co. There is 1 mg of finasteride in Propecia and 5 mg in Proscar. Merck's patent on finasteride for the treatment of BPH expired in June 2006. Merck was awarded a separate patent for the use of finasteride to treat pattern hair loss and it expired in November 2013. Finasteride is also marketed under a variety of other brand names throughout the world.
== External links == molecularfarming.com Official site Molecular Farming – Plant Bioreactors Moss bioreactors do not smell (Interview with Ralf Reski) Molecular Pharming – pharmaceuticals with the help of GM plants Pharming for Farmaceuticals "Pharming the Field: A Look at the Benefits and Risks of Bioengineering Plants to Produce Pharmaceuticals". The Pew Charitable Trusts. July 18, 2002. USDA-APHIS Biotechnology Regulatory Services[link removed] EPA Biotechnology page FDA Biotechnology page Archived 2009-05-17 at the Wayback Machine Homepage of the Coordinated Framework for Regulation of Biotechnology Draft Guidance for APHIS Permits for Field Testing or Movement of Organisms with Pharmaceutical or Industrial Intent PlantPharma.org Online Community Archived 2021-04-18 at the Wayback Machine National Science Foundation Pharma-Planta Consortium Biotechnology Industry Organization Society for Moleculture, a non-for-profit organisation for plant- factories, Québec, Canada
(which is true for all aqueous solutions), and the constraint that the solution must be electrically neutral, i.e., the overall charge of dissolved positive ions [Ca2+] + 2 [H+] must be cancelled out by the overall charge of dissolved negative ions [HCO−3] + [CO2−3] + [OH−], make it possible to solve simultaneously for the remaining five unknown concentrations (the previously mentioned form of the neutrality is valid only if calcium carbonate has been put in contact with pure water or with a neutral pH solution; in the case where the initial water solvent pH is not neutral, the balance is not neutral). The adjacent table shows the result for [Ca2+] and [H+] (in the form of pH) as a function of ambient partial pressure of CO2 (Ksp = 4.47×10−9 has been taken for the calculation).
Sources: en.wikipedia.org
Following this, the European Green Party presented the European Parliament copies of contracts signed by two European companies and representatives of the President of Somalia, to accept 10 million tonnes of toxic waste for $80 million. According to reports by the United Nations Environment Programme (UNEP), the waste resulted in abnormally high cases of respiratory infections, mouth ulcers, mouth bleeding, abdominal haemorrhages and unusual skin infections among the inhabitants of and around the northeastern towns of Hobyo and Benadir. These diseases were consistent with radiation sickness. UNEP adds that the situation posed a very serious environmental hazard to Somalia and the broader eastern Africa sub-region.
=== Origins === Capsicum plants originated in modern-day Peru and Bolivia, and have been a part of human diets since about 7,500 BC. They are one of the oldest cultivated crops in the Americas. Chili peppers were cultivated in east-central Mexico some 6,000 years ago, and independently across different locations in the Americas including highland Peru and Bolivia, central Mexico, and the Amazon. They were among the first self-pollinating crops cultivated in those areas. Peru has the highest diversity of cultivated Capsicum; it is a center of diversification where varieties of all five domesticates were introduced, grown, and consumed in pre-Columbian times. The largest diversity of wild Capsicum peppers is consumed in Bolivia. Bolivian consumers distinguish two basic forms: ulupicas, species with small round fruits including C. eximium, C. cardenasii, C. eshbaughii, and C. caballeroi landraces; and arivivis with small elongated fruits including C. baccatum var. baccatum and C. chacoense varieties.
== Reactions == The cycle comprises three enzyme-catalysed reactions. The first stage is the deamination of the purine nucleotide adenosine monophosphate (AMP) to form inosine monophosphate (IMP), catalysed by the enzyme AMP deaminase:
Sources: en.wikipedia.org
==== Corneal Allogenic Intrastromal Ring Segments (CAIRS) ==== Corneal Allogenic Intrastromal Ring Segment Keratoplasty (CAIRS Keratoplasty) is a modern surgical technique used in the treatment of keratoconus. It involves implanting finely shaped pieces of donor corneal tissue into the corneal stroma to reinforce and reshape the weakened, ectatic cornea, thereby improving both corneal structure and visual clarity. Because CAIRS uses biological graft material and has demonstrated strong outcomes with a favourable safety profile, it is formally recognised as a corneal transplantation procedure by health funding authorities in Australia, the United Kingdom, Japan, Germany, Brazil, the Netherlands, and a number of other countries. In contrast to traditional synthetic intrastromal corneal ring segments (ICRS) made from materials such as PMMA, CAIRS keratoplasty uses preserved allogeneic corneal tissue. This biological compatibility reduces the likelihood of complications sometimes seen with non-organic implants, including extrusion, infection, or chronic foreign body reaction. The CAIRS technique was pioneered by Dr Soosan Jacob, who first introduced it in 2018 through a large case series published in the Journal of Refractive Surgery. One of its key strengths is its suitability for corneas with irregular or decentered cones. The donor segments can be individually designed to achieve targeted corneal flattening and astigmatism improvement.
CPC Scientific’s manufacturing processes primarily use solid-phase peptide synthesis (SPPS), first described by Robert Bruce Merrifield in 1963. SPPS allows peptides to be assembled stepwise on a solid support, enabling the preparation of long and complex sequences for use as active pharmaceutical ingredients (APIs), investigational drugs, and research materials. Researchers associated with the company have published studies involving peptide synthesis methodologies, including work related to hydrocarbon stapling. Products manufactured by the company have been used and cited in various scientific studies. Official website
Distal membrane-arm assembly complex protein 1 is a protein that in humans is encoded by the DMAC1 gene (previously TMEM261). TMEM261 is also known as C9ORF123 and DMAC1, Chromosome 9 Open Reading Frame 123 and Transmembrane Protein C9orf123 and Distal membrane-arm assembly complex protein 1. TMEM261 is located at 9p24.1, its length is 91,891 base pairs (bp) on the reverse strand. Its neighbouring gene is PTPRD located at 9p23-p24.3 also on the reverse strand and encodes protein tyrosine phosphatase receptor type delta. TMEM261 has 2 exons and 1 intron, and 6 primary transcript variants; the largest mRNA transcript variant consisting of 742bp with a protein 129 amino acids (aa) in length and 13,500 daltons (Da) in size, and the smallest coding transcript variant being 381bp with a protein 69aa long and 6,100 Da in size. TMEM261 is a protein consisting out of 112 amino acids, with a molecular weight of 11.8 kDa. The isoelectric point is predicted to be 10.2, whilst its posttranslational modification value is 9.9.
In vitro testing suggests that unidentified wolfberry phytochemicals in goji tea may inhibit metabolism of medications, such as those processed by the cytochrome P450 liver enzymes, including such drugs as warfarin. Organochlorine pesticides are conventionally used in commercial wolfberry cultivation to mitigate infestation by insects. China's Green Food Standard, administered by the Chinese Ministry of Agriculture's China Green Food Development Center, permits some pesticide and herbicide use. Agriculture in the Tibetan Plateau (where many "Himalayan" or "Tibetan"-branded berries supposedly originate) conventionally uses fertilizers and pesticides, making organic claims for berries originating there dubious. Since the early 21st century, high levels of insecticide residues (including fenvalerate, cypermethrin, and acetamiprid) and fungicide residues (such as triadimenol and isoprothiolane), have been detected by the United States Food and Drug Administration in some imported wolfberries and wolfberry products of Chinese origin, leading to the seizure of these products.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.